Creso Pharma (ASX:CPH) ends June quarter with revenue growth

• Creso Pharma (CPH) ends the June quarter with $1.63 million worth of generated revenue, an 18 per cent increase on its March figures
• The company says its Canadian cannabis business bought in $966,459 worth of revenue, while its Swiss nutraceutical business notched up $607,344
• CPH ended June cashflow negative and with $13.56 million in the bank, topping up that balance over July to end the month with $16 million
• It also signed an agreement with Red Light Holland to merge, listed on the US OTCQB market and acquired psychedelic's business Halucenex Life Sciences

Read the Full Article on The Market Herald here